ID   NB4-AsR
AC   CVCL_U080
SY   NB4-dT-AsR1
DR   cancercelllines; CVCL_U080
DR   Wikidata; Q54907528
RX   PubMed=9596679;
RX   PubMed=11704857;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; As2O3).
CC   Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3182; Acute promyelocytic leukemia with PML-RARA
DI   ORDO; Orphanet_520; Acute promyelocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0005 ! NB4
SX   Female
AG   23Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 18
//
RX   PubMed=9596679; DOI=10.1182/blood.V91.11.4300;
RA   Gianni M., Koken M.H.M., Chelbi-Alix M.K., Benoit G., Lanotte M.,
RA   Chen Z., de The H.;
RT   "Combined arsenic and retinoic acid treatment enhances differentiation
RT   and apoptosis in arsenic-resistant NB4 cells.";
RL   Blood 91:4300-4310(1998).
//
RX   PubMed=11704857; DOI=10.1038/sj.onc.1204863;
RA   Roussel M.J.S., Lanotte M.;
RT   "Maturation sensitive and resistant t(15;17) NB4 cell lines as tools
RT   for APL physiopathology: nomenclature of cells and repertory of their
RT   known genetic alterations and phenotypes.";
RL   Oncogene 20:7287-7291(2001).
//